Softgel Capsules Market (2026 - 2033)

Softgel Capsules Market Summary

The global softgel capsules market size was valued at USD 8.5 billion in 2025 and is projected to grow from USD 9.1 billion in 2026 to USD 15.4 billion by 2033, at a CAGR of 7.9% from 2026 to 2033. North America dominated the market, accounting for the largest global share of 41.2% in 2025. The softgel capsules market is experiencing steady growth, supported by increasing demand from the pharmaceutical, nutraceutical, and over-the-counter healthcare industries. 

Rising consumption of dietary supplements, preventive healthcare products, and specialty oral formulations continues to expand the use of softgel capsules across developed and emerging markets. Pharmaceutical manufacturers are increasing the use of softgel dosage forms for products requiring improved bioavailability, dose accuracy, and formulation stability, while nutraceutical companies are expanding product portfolios to address growing consumer interest in vitamins, minerals, omega-3 supplements, and herbal formulations.

Contract development and manufacturing organizations are also strengthening softgel manufacturing capacity as pharmaceutical and consumer health companies continue to outsource production. In addition, manufacturers are investing in advanced encapsulation technologies, vegetarian capsule materials, and production automation to improve manufacturing efficiency and meet changing regulatory and consumer requirements. Growth in e-commerce distribution, expanding healthcare access, and continued product innovation across pharmaceutical and consumer health categories are supporting the market's development across major regional markets.

Market Dynamics

Market Concentration & Characteristics

Innovation remains high as manufacturers continue to develop advanced encapsulation technologies to improve formulation performance and meet changing pharmaceutical requirements. Companies are focusing on lipid-based drug delivery systems, modified-release softgels, plant-based capsule materials, oxygen barrier technologies, and improved encapsulation processes. Continuous research aimed at enhancing bioavailability, ingredient stability, capsule integrity, and compatibility with complex active pharmaceutical ingredients is expanding the application of softgel dosage forms across pharmaceuticals and nutraceuticals.

The market has high entry barriers due to the capital-intensive nature of softgel manufacturing and strict regulatory requirements. Establishing production facilities requires specialized encapsulation equipment, controlled manufacturing environments, validated quality systems, and compliance with Good Manufacturing Practice (GMP) standards. New entrants must also develop formulation expertise, secure reliable raw material supply chains, obtain regulatory certifications, and build customer confidence before competing with established manufacturers.

Regulatory compliance has a significant influence on the softgel capsules market because manufacturers supplying pharmaceutical and dietary supplement products must meet strict quality, safety, and manufacturing standards. Compliance with GMP requirements, pharmacopeial specifications, ingredient traceability, stability testing, and product documentation is essential for market access. Regulatory inspections and quality audits also require continuous investments in manufacturing systems, quality assurance, and process validation across production facilities.Product substitution is moderate because tablets, hard capsules, powders, sachets, gummies, and liquid formulations provide alternative oral dosage forms for many pharmaceutical and nutraceutical products. However, softgel capsules remain the preferred option for lipid-based formulations, fat-soluble ingredients, and poorly water-soluble active pharmaceutical ingredients due to their ability to improve formulation stability, dose uniformity, and patient convenience, limiting substitution in several applications.

Geographical expansion remains high as pharmaceutical and nutraceutical manufacturers increase production and distribution across Asia Pacific, Latin America, the Middle East, and other developing markets. Rising healthcare expenditure, increasing dietary supplement consumption, expanding pharmaceutical manufacturing capacity, and growing contract manufacturing activities are encouraging companies to establish new production facilities, expand regional partnerships, and strengthen global supply chains.

Analyst Perspective

The softgel capsules market is driven by increasing demand for oral dosage formulations across pharmaceuticals and nutraceuticals. Manufacturers are expanding formulation capabilities, adopting plant-based capsule materials, and improving encapsulation technologies. Growth in pharmaceutical manufacturing and continued product development are supporting demand across prescription medicines, over-the-counter products, and dietary supplements.

Type Insights

The gelatin-based/animal-based segment dominated the market and accounted for the largest revenue share of 83.4% in 2025, due to its extensive use across pharmaceutical, nutraceutical, and over-the-counter healthcare products. Gelatin-based softgel capsules provide high mechanical strength, reliable sealing performance, and compatibility with a broad range of liquid and semi-solid formulations, making them a preferred choice for manufacturers. The segment benefits from established manufacturing processes, broad regulatory acceptance, and cost-effective large-scale production. In addition, increasing demand for lipid-based drug formulations, omega-3 supplements, fat-soluble vitamins, and herbal extracts continues to support product adoption. Pharmaceutical companies and contract development and manufacturing organizations (CDMOs) also prefer gelatin-based capsules because of their formulation flexibility, production efficiency, and ability to protect moisture-sensitive ingredients, supporting continued demand across global pharmaceutical and nutraceutical industries.

The non-animal-based segment is projected to grow at a CAGR of 13.3% over the forecast period, driven by increasing demand for vegetarian and vegan pharmaceutical and nutraceutical products. Manufacturers are expanding the use of pullulan, hydroxypropyl methylcellulose (HPMC), and starch-based materials to meet changing consumer preferences and address dietary, religious, and sustainability considerations. The segment is also benefiting from improvements in capsule materials that provide enhanced stability, oxygen barrier properties, and compatibility with complex active ingredients. Pharmaceutical companies are increasingly incorporating non-animal softgel capsules into new product development to broaden consumer reach and comply with regional market requirements. In addition, investments in plant-based encapsulation technologies and manufacturing capabilities are supporting greater product availability, enabling manufacturers to expand their portfolios across dietary supplements, functional nutrition products, and prescription medicines.

Application Insights

The vitamin and dietary supplement segment dominated the market and accounted for the largest revenue share of 23.2% in 2025, owing to the increasing global consumption of nutritional supplements for preventive healthcare and wellness. Softgel capsules are widely preferred for delivering vitamins, minerals, omega-3 fatty acids, and botanical extracts because they provide accurate dosing, improved ingredient stability, and ease of swallowing. The segment is supported by growing awareness of nutritional deficiencies, an aging population, and rising demand for self-care products across developed and emerging markets. In addition, manufacturers continue to expand product portfolios with specialized formulations targeting immunity, cardiovascular health, bone health, and cognitive function. The widespread availability of these products through retail stores, pharmacies, and online platforms further supports the adoption of softgel-based vitamin and dietary supplements.

The health supplement segment is projected to grow at a CAGR of 9.5% over the forecast period, driven by increasing consumer focus on preventive healthcare and functional nutrition. Demand for health supplements containing probiotics, herbal extracts, antioxidants, and specialty nutritional ingredients continues to increase as consumers seek products that support overall health and well-being. Softgel capsules are increasingly used for these formulations because they protect sensitive ingredients, improve formulation stability, and enhance consumer convenience. Manufacturers are also introducing clean-label, plant-based, and customized health supplement formulations to address changing consumer preferences. In addition, expanding e-commerce distribution, increasing health awareness, and continued product innovation are supporting the growth of health supplement applications across both mature and emerging healthcare markets.

End-use Insights

The pharmaceutical companies segment dominated the market and accounted for the largest revenue share of 51.8% in 2025, due to the extensive use of softgel capsules for prescription medicines, over-the-counter products, and specialty pharmaceutical formulations. Pharmaceutical companies continue to adopt softgel technology for products requiring improved bioavailability, formulation stability, and precise dosing, particularly for lipid-based and poorly water-soluble active pharmaceutical ingredients. The segment is also supported by ongoing research and development activities, increasing production of oral solid dosage forms, and the expansion of specialty drug portfolios. In addition, pharmaceutical manufacturers continue to invest in advanced formulation technologies and collaborate with specialized manufacturing partners to improve product quality and accelerate commercialization across global markets.

The nutraceutical companies segment is projected to grow at a CAGR of 10.0% over the forecast period, supported by increasing demand for dietary supplements, functional nutrition products, and wellness formulations. Nutraceutical companies are expanding their product portfolios with vitamins, minerals, omega-3 fatty acids, herbal extracts, probiotics, and other specialty ingredients that are commonly delivered through softgel capsules. The segment is benefiting from growing consumer awareness of preventive healthcare, increasing disposable incomes, and rising adoption of daily nutritional supplements. Manufacturers are also focusing on innovative formulations, clean-label ingredients, and plant-based softgel technologies to meet changing consumer preferences. Continued expansion of online retail channels and wider product availability are further supporting the growth of nutraceutical companies in the softgel capsules market.

Regional Insights

North America held the largest softgel capsules market share of 41.2% in 2025, driven by the region's well-established pharmaceutical and nutraceutical manufacturing industry, high consumption of dietary supplements, and increasing adoption of advanced oral dosage formulations. The market benefits from the strong presence of pharmaceutical companies, nutraceutical manufacturers, and contract development and manufacturing organizations (CDMOs) with established softgel production capabilities and advanced encapsulation technologies. Rising demand for vitamin and dietary supplements, health supplements, prescription medicines, and over-the-counter products continues to support the use of gelatin-based and non-animal-based softgel capsules across the region. In addition, increasing development of lipid-based drug formulations, growing outsourcing of manufacturing activities, and continued adoption of plant-based capsule technologies are supporting product innovation across pharmaceutical and nutraceutical applications. A well-established regulatory framework, advanced manufacturing infrastructure, and strong investment in formulation research continue to support market expansion. The presence of leading capsule manufacturers, CDMOs, and nutraceutical companies, combined with ongoing investments in production capacity and encapsulation technologies, further strengthens regional market growth.

U.S. Softgel Capsules Market Trends

The U.S. softgel capsules market is supported by increasing demand for high-value oral drug formulations, expanding production of nutraceutical products, and continuous investment in pharmaceutical manufacturing capabilities. The country has a strong network of formulation developers, capsule manufacturers, and contract development and manufacturing organizations (CDMOs) that facilitate the production of softgel capsules for prescription drugs, over-the-counter medicines, vitamins, dietary supplements, and specialty health products. Growing demand for lipid-based formulations and complex oral delivery systems has encouraged manufacturers to adopt advanced encapsulation technologies that improve ingredient stability and bioavailability. The market is also benefiting from rising consumer preference for preventive healthcare products, increasing adoption of plant-based capsule materials, and expanding private-label supplement manufacturing. In addition, continuous investments in research and development, process automation, and quality-focused manufacturing are strengthening domestic production capabilities. Collaboration between pharmaceutical companies, nutraceutical manufacturers, and specialized CDMOs continues to support formulation innovation and expand the availability of softgel capsule products across therapeutic and wellness applications in the U.S. market.

Europe Softgel Capsules Market Trends

Europe softgel capsules market is driven by the region's established pharmaceutical manufacturing base, increasing demand for nutritional supplements, and growing adoption of advanced oral drug delivery technologies. The market benefits from the presence of leading pharmaceutical companies, capsule manufacturers, and contract development and manufacturing organizations (CDMOs) that support the production of softgel formulations for prescription medicines, over-the-counter products, vitamins, and dietary supplements. Rising demand for preventive healthcare products, coupled with increasing consumer preference for clean-label and plant-based formulations, is accelerating the adoption of non-animal-based softgel capsules across the region. In addition, continuous development of lipid-based formulations, expanding use of softgel technology for poorly water-soluble active pharmaceutical ingredients, and increasing outsourcing of manufacturing activities are supporting product innovation and manufacturing efficiency. The region's harmonized pharmaceutical regulatory framework, strong research capabilities, and emphasis on quality manufacturing standards continue to facilitate the development of advanced softgel formulations. Ongoing investments in sustainable capsule materials, formulation technologies, and production capacity further support the growth of the Europe softgel capsules market.

The UK softgel capsules market is driven by the country's growing demand for nutraceutical products, expanding pharmaceutical formulation activities, and increasing preference for convenient oral dosage forms. The market benefits from an established life sciences sector, advanced pharmaceutical research capabilities, and a strong network of contract development and manufacturing organizations supporting softgel formulation and production. Rising consumption of vitamin and dietary supplements, sports nutrition products, and preventive healthcare formulations continues to increase demand for both gelatin-based and non-animal-based softgel capsules. In addition, increasing adoption of lipid-based drug delivery technologies and plant-based capsule materials is supporting the development of differentiated pharmaceutical and nutraceutical products. A well-established regulatory framework, strong quality standards, and continued investment in pharmaceutical manufacturing and research facilitate the development of advanced softgel formulations. The presence of specialized formulation companies, capsule manufacturers, and nutraceutical producers, together with ongoing investments in manufacturing technologies and product innovation, continues to support the growth of the UK softgel capsules market.

The Germany softgel capsules market is driven by the country's strong pharmaceutical manufacturing sector, growing demand for dietary supplements, and increasing adoption of advanced oral dosage technologies. The market benefits from a well-established pharmaceutical and life sciences ecosystem, supported by specialized formulation companies, capsule manufacturers, and contract development and manufacturing organizations (CDMOs) with expertise in softgel production. Rising consumption of vitamin and dietary supplements, preventive healthcare products, and prescription medicines continues to support demand for gelatin-based and non-animal-based softgel capsules across pharmaceutical and nutraceutical applications. In addition, increasing use of lipid-based drug delivery systems, expanding adoption of plant-based capsule materials, and continuous development of complex oral formulations are contributing to product innovation and wider application of softgel technologies. Germany's stringent pharmaceutical quality standards, advanced manufacturing capabilities, and strong emphasis on research and development continue to support the production of high-quality softgel formulations. The presence of leading pharmaceutical companies, capsule technology providers, and contract manufacturers, together with ongoing investments in formulation development and manufacturing modernization, continues to support the growth of the Germany softgel capsules market.

The France softgel capsules market is driven by the country's established pharmaceutical industry, increasing demand for nutraceutical products, and growing preference for convenient oral dosage formulations. The market is supported by a well-developed healthcare and life sciences ecosystem, with pharmaceutical manufacturers, nutraceutical companies, research institutions, and contract development and manufacturing organizations (CDMOs) contributing to the development and production of softgel capsule formulations. Rising consumption of vitamin and dietary supplements, preventive healthcare products, and over-the-counter medicines continues to support demand for both gelatin-based and non-animal-based softgel capsules across pharmaceutical and wellness applications. In addition, increasing adoption of lipid-based drug delivery technologies, expanding use of plant-derived capsule materials, and continuous development of formulation technologies are broadening the application of softgel dosage forms for complex active pharmaceutical ingredients. France's robust pharmaceutical regulatory framework, strong research capabilities, and emphasis on high-quality manufacturing continue to support the development of advanced softgel formulations. The presence of leading pharmaceutical companies, specialized formulation developers, and contract manufacturers, together with continued investments in product development and manufacturing technologies, continues to support the growth of the France softgel capsules market.

Asia Pacific Softgel Capsules Market Trends

Asia Pacific is projected to register the fastest CAGR of 5.6% during the forecast period. The Asia Pacific softgel capsules market is driven by the rapid expansion of the pharmaceutical and nutraceutical industries, increasing healthcare expenditure, and growing demand for convenient oral dosage formulations across developing and developed economies. The region benefits from an expanding pharmaceutical manufacturing ecosystem supported by contract development and manufacturing organizations (CDMOs), ingredient suppliers, formulation developers, and capsule manufacturers that are strengthening regional production capabilities. Rising consumer awareness of preventive healthcare, increasing consumption of vitamin and dietary supplements, sports nutrition products, and over-the-counter medicines continue to support demand for gelatin-based and non-animal-based softgel capsules across the region. In addition, growing adoption of lipid-based drug delivery systems, increasing use of plant-based capsule materials, and continued advancements in encapsulation technologies are expanding the application of softgel capsules for pharmaceutical and nutraceutical products. Supportive regulatory initiatives, expanding pharmaceutical manufacturing capacity, and increasing investments in research and development continue to strengthen the regional industry. The presence of a large consumer base, improving healthcare infrastructure, and continuous investments by domestic and multinational companies in manufacturing expansion and product innovation continue to support the growth of the Asia Pacific softgel capsules market.

The Japan softgel capsules market is driven by the country's advanced pharmaceutical industry, increasing demand for nutraceutical products, and growing preference for convenient oral dosage formulations among its aging population. The market is supported by a well-established pharmaceutical and life sciences ecosystem, with pharmaceutical manufacturers, formulation developers, capsule manufacturers, and contract development and manufacturing organizations (CDMOs) contributing to the development and production of softgel formulations. Rising consumption of vitamin and dietary supplements, functional foods, preventive healthcare products, and over-the-counter medicines continues to support demand for gelatin-based and non-animal-based softgel capsules across pharmaceutical and nutraceutical applications. In addition, increasing adoption of lipid-based drug delivery systems, continued advancements in formulation technologies, and the development of high-quality encapsulation processes are expanding the application of softgel capsules for complex pharmaceutical and nutritional ingredients. Japan's stringent pharmaceutical quality standards, strong research and development capabilities, and emphasis on product quality continue to support innovation in softgel formulation and manufacturing. The presence of established pharmaceutical companies, specialized softgel manufacturers, ingredient suppliers, and contract manufacturing organizations, together with continuous advancements in formulation development and manufacturing technologies, continues to support the growth of the Japan softgel capsules market.

The China softgel capsules market is driven by the rapid expansion of the pharmaceutical and nutraceutical industries, increasing healthcare expenditure, and growing demand for convenient oral dosage formulations across a large patient and consumer population. The market benefits from a well-developed pharmaceutical manufacturing ecosystem, supported by active pharmaceutical ingredient manufacturers, formulation companies, capsule producers, and contract development and manufacturing organizations (CDMOs) that continue to strengthen domestic production capabilities. Rising consumption of vitamin and dietary supplements, functional nutrition products, traditional herbal formulations, and over-the-counter medicines continues to support demand for gelatin-based and non-animal-based softgel capsules across pharmaceutical and nutraceutical applications. In addition, increasing adoption of lipid-based drug delivery technologies, expanding use of plant-based capsule materials, and continuous advancements in formulation and encapsulation technologies are broadening the application of softgel capsules for complex active ingredients. Government initiatives supporting pharmaceutical innovation, manufacturing modernization, and quality improvements continue to strengthen the country's production capabilities and product development activities. The presence of large pharmaceutical companies, specialized softgel manufacturers, ingredient suppliers, and contract manufacturing organizations, together with continuous advancements in formulation development and manufacturing technologies, continues to support the growth of the China softgel capsules market.

Latin America Softgel Capsules Market Trends

The Latin America softgel capsules market is driven by the expanding pharmaceutical and nutraceutical industries, increasing healthcare expenditure, and growing demand for convenient oral dosage formulations across the region. The market is supported by the continued development of pharmaceutical manufacturing capabilities, expanding contract manufacturing activities, and the growing presence of domestic and multinational pharmaceutical companies. Rising consumer awareness of preventive healthcare, increasing consumption of vitamin and dietary supplements, herbal products, and over-the-counter medicines continue to support demand for gelatin-based and non-animal-based softgel capsules across pharmaceutical and nutraceutical applications. In addition, increasing adoption of lipid-based drug delivery technologies, wider use of plant-based capsule materials, and ongoing improvements in formulation and encapsulation technologies are expanding the application of softgel capsules for a broad range of pharmaceutical and nutritional products. Regulatory improvements, growing investments in pharmaceutical manufacturing, and expanding access to healthcare services continue to strengthen regional production capabilities and product availability. The presence of pharmaceutical manufacturers, nutraceutical companies, capsule producers, and contract manufacturing organizations, together with continued advancements in formulation development and manufacturing technologies, continues to support the growth of the Latin America softgel capsules market.

The Brazil softgel capsules market is driven by the country's expanding domestic pharmaceutical production, growing dietary supplement industry, and increasing consumer preference for convenient oral dosage forms. Brazil serves as one of the largest pharmaceutical manufacturing hubs in Latin America, supported by a strong network of domestic drug manufacturers, multinational pharmaceutical companies, and contract manufacturing organizations that continue to expand local production capabilities. The increasing use of vitamins, omega-3 supplements, sports nutrition products, herbal medicines, and beauty-from-within nutraceuticals is strengthening demand for softgel capsule formulations across retail and pharmacy channels. In addition, pharmaceutical companies are expanding the use of softgel technology to improve the bioavailability of poorly water-soluble active ingredients while supporting differentiated formulations for prescription and over-the-counter products. ANVISA's regulatory framework, continued investments in local pharmaceutical manufacturing, and growing adoption of advanced encapsulation technologies are supporting product quality and manufacturing efficiency. The presence of established pharmaceutical manufacturers, nutraceutical producers, specialized softgel manufacturers, and contract development and manufacturing organizations, together with continued investments in formulation development and modern production technologies, continues to support the growth of the Brazil softgel capsules market.

Middle East & Africa Softgel Capsules Market Trends

The Middle East & Africa softgel capsules market is driven by the expansion of the pharmaceutical sector, increasing demand for dietary supplements, and improving access to healthcare across several countries in the region. Growing government initiatives to strengthen local pharmaceutical manufacturing, particularly in countries such as Saudi Arabia, the UAE, Egypt, and South Africa, are supporting the production and supply of oral solid dosage formulations, including softgel capsules. Rising consumer awareness of preventive healthcare, coupled with increasing use of vitamins, minerals, omega-3 supplements, and herbal products, continues to support demand across retail pharmacies and health supplement channels. In addition, pharmaceutical manufacturers are adopting softgel capsule technologies for lipid-based formulations and bioavailability enhancement of poorly soluble active pharmaceutical ingredients, supporting the development of differentiated prescription and over-the-counter products. Regulatory modernization, increasing investments in domestic pharmaceutical production, and expansion of contract manufacturing capabilities are strengthening the regional manufacturing ecosystem. The presence of multinational pharmaceutical companies, regional drug manufacturers, nutraceutical producers, and contract manufacturing organizations, together with ongoing investments in formulation development and manufacturing technologies, continues to support the growth of the Middle East & Africa softgel capsules market.

The Saudi Arabia softgel capsules market is driven by the country's ongoing pharmaceutical sector transformation under Vision 2030, increasing localization of pharmaceutical manufacturing, and rising demand for high-quality oral dosage formulations. Government initiatives to strengthen domestic drug production and reduce reliance on imported medicines are encouraging investments in pharmaceutical manufacturing facilities, contract manufacturing partnerships, and technology transfer agreements. Growing consumer spending on preventive healthcare, coupled with increasing use of vitamins, minerals, omega-3 supplements, halal-certified nutraceuticals, and herbal health products, continues to support demand for softgel capsules through retail pharmacies, hospital pharmacies, and e-commerce channels. In addition, pharmaceutical manufacturers are adopting advanced softgel encapsulation technologies to improve the stability and bioavailability of lipid-soluble ingredients while expanding local production of prescription and over-the-counter formulations. The regulatory oversight of the Saudi Food and Drug Authority (SFDA), continued investments in pharmaceutical industrial zones, and expanding domestic manufacturing capabilities are strengthening the country's pharmaceutical value chain. The presence of multinational pharmaceutical companies, regional manufacturers, nutraceutical producers, and contract manufacturing organizations, together with continued investments in advanced formulation development and production technologies, continues to support the growth of the Saudi Arabia softgel capsules market.

Key Softgel Capsules Company Insights

The softgel capsules market is highly competitive, with CDMOs, capsule technology providers, and nutraceutical manufacturers competing through formulation expertise, manufacturing capacity, regulatory compliance, and customized production services. Catalent, Inc. and Aenova Group are leading providers of end-to-end softgel development, encapsulation, packaging, and commercial manufacturing. Lonza Capsules & Health Ingredients strengthens the market with gelatin and plant-based capsule technologies for pharmaceutical and nutraceutical applications. Sirio Pharma Co., Ltd., Fuji Capsule, and ProCaps Laboratories focus on customized formulations and private-label manufacturing to meet rising demand for dietary supplements and over-the-counter healthcare products. Soft Gel Technologies, EuroCaps, and CAPTEK Softgel International enhance competition through specialized encapsulation and formulation capabilities. Thermo Fisher Scientific supports quality control and manufacturing technologies, while EyePoint Pharmaceuticals contributes advanced drug delivery expertise. Market growth is driven by outsourcing to CDMOs, capacity expansion, technological innovation, and increasing demand for differentiated softgel formulations across healthcare sectors.

Key Softgel Capsules Companies:

• Fuji Capsule

• Sirio Pharma Co., Ltd.

• CAPTEK Softgel International Inc.

• Thermo Fisher Scientific Inc.

• EyePoint Pharmaceuticals, Inc.

• Catalent, Inc.

• EuroCaps

• Aenova Group

• Lonza Capsules & Health Ingredients

• ProCaps Laboratories, LLC

• Soft Gel Technologies, Inc.

Competitive Benchmarking

Recent Developments

• In May 2026, Lonza Capsules & Health Ingredients announced new peer-reviewed data demonstrating the performance of its Licaps DUOCAP capsule-in-capsule technology. The study showed that the technology delivered up to four times higher enzyme activity in the upper small intestine compared to standard immediate-release capsules, supporting advanced oral delivery applications for nutraceutical formulations.

• In March 2026, Lonza announced an agreement to divest its Capsules & Health Ingredients business to Lone Star Funds. The transaction was intended to establish the Capsules & Health Ingredients business as an independent company with a dedicated focus on capsule technologies and health ingredients, enabling greater operational flexibility and continued development of capsule solutions for the pharmaceutical and nutraceutical industries.

• In March 2025, Lonza Capsules & Health Ingredients established its Center of Applied Sustainability to support capsule innovation across the pharmaceutical and nutraceutical industries. The center was created to integrate sustainability into capsule design, raw material selection, manufacturing processes, and customer collaboration, supporting the development of gelatin and plant-based capsule solutions with improved environmental performance.

Softgel Capsules Market Report Scope

Global Softgel Capsules Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global softgel capsules market report based on type, application, end-use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Gelatin-Based/Animal-Based

  • Non-Animal-Based

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Antacid and Anti-Flatulent Preparation

  • Anti-Anemic Preparations

  • Anti-Inflammatory Drugs

  • Antibiotic and Antibacterial Drugs

  • Cough and Cold Preparations

  • Health Supplement

  • Vitamin and Dietary Supplement

  • Pregnancy

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharmaceutical Companies

  • Nutraceutical Companies

  • Cosmeceutical Companies

  • Contract Manufacturing Organization

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The softgel capsules market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each softgel capsules segment quantified using the revenue-capture definitions in the table below.

Segment Definition

Estimation Model

The softgel capsules market is estimated using a revenue-based commodity flow approach. The methodology begins with identifying key manufacturers, contract development and manufacturing organizations, and nutraceutical companies involved in softgel capsule production. Product portfolios are benchmarked by capsule type, application, end use, manufacturing capacity, and geographic presence. Revenue generated from softgel capsule products and manufacturing services is evaluated using annual reports, investor presentations, regulatory filings, company websites, trade publications, and industry databases. Revenue contribution from pharmaceutical, nutraceutical, over the counter, and dietary supplement applications is assessed to estimate the existing market.

The revenues generated by major participants are consolidated and adjusted based on the presence of regional and private manufacturers to derive the overall market size. The estimates are validated through production volumes, manufacturing capacity utilization, import-export statistics, pricing trends, distributor insights, and interviews with industry participants to ensure consistent market estimates.

Delivered Customizations

This report has been delivered with the following In-depth customizations